Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current. 

Category
done
done
done
Displaying 1 - 38 of 38
Date Sort ascending
CL_2024-38.pdf

ACTION REQUIRED
CBS Manufactured Pathogen Reduced Apheresis Frozen Plasma: Revised Implementation date and new associated ISBT Component Codes

Customer Letter 2024-38 (PDF)

CL_2024-37.pdf

INFORMATION ONLY
Grifols Product Packaging Update – Carton Security Seal

Customer Letter 2024-37 (PDF)Grifols Product Packaging Update - Carton Security Seal (PDF)

CL_2024-36.pdf

INFORMATION ONLY
Octaplasma Labelling Updates – Batch and Expiry Dating Formatting

Customer Letter 2024-36 (PDF) | Octaplasma® Labelling Updates – Batch and Expiry Dating Formatting (PDF)

CL_2024-35.pdf

INFORMATION ONLY
New Shipping Containers to be Phased In

Customer Letter 2024-35 (PDF)

CL_2024-34.pdf

INFORMATION ONLY
Leukoreduced Whole Blood Clinical Studies: Second Update

Customer Letter 2024-34 (PDF) | Canadian Blood Services Leukoreduced Whole Blood Program for Non-Military Use (PDF)

CL_2024-33.pdf

INFORMATION ONLY
SD Plasma Expiry Date Discrepancy

Customer Letter 2024-33 (PDF) | Octaplasma Difference in Date Formatting (PDF)​​​​​​

CL_2024-32.pdf

INFORMATION ONLY
Introduction of CBS Manufactured Pathogen Reduced Plasma (Apheresis Multiplasma)

Customer Letter 2024-32 (PDF)

CL_2024-31.pdf

INFORMATION ONLY
New PPRP Content Sheet for Shipping Box

Customer Letter 2024-31 (PDF)

CL_2024-30.pdf

INFORMATION ONLY
Leukoreduced Whole Blood Clinical Studies

Customer Letter 2024-30 (PDF)

CL_2024-29.pdf

INFORMATION ONLY
Replacement of Plasma Protein and Related Products (PPRP) Customer Table of Information with E-Formulary

Customer Letter 2024-29 (PDF)

CL_2024-28.pdf

INFORMATION ONLY
Bayer Introduction of 2-Dimensional Barcodes

Customer Letter 2024-28 (PDF) | Bayer Letter (PDF)

CL_2024-27.pdf

INFORMATION ONLY
Gammagard SD Label and Diluent Update

Customer Letter 2024-27 (PDF) | Takeda Letter (PDF)

CL_2024-26.pdf

INFORMATION ONLY
Updated Glassia Implementation FAQ (version 2)

Customer Letter 2024-26 (PDF) | Glassia Implementation FAQ Version 2 (PDF)

CL_2024-25.pdf

INFORMATION ONLY
Form Change – Manitoba Hospital Customers Only – Platelet Immunology Laboratory, HLA Disease Association

Customer Letter 2024-25 (PDF)

CL_2024-24.pdf

INFORMATION ONLY
Formulary Delisting of WinRho 5000 IU

Customer Letter 2024-24 (PDF)

CL_2024-23.pdf

INFORMATION ONLY
SD Plasma Expiry Dates

Customer Letter 2024-23 (PDF) | Plasma Expiry Date Examples (PDF) | Variable Data (PDF)

CL_2024-22.pdf

INFORMATION ONLY
Updated Hospital Customer Order Forms – Special Request Order Form and Hospital Customer Order Form

Customer Letter 2024-22 (PDF)

CL_2024-21.pdf

INFORMATION ONLY
Ondexxya (andexanet alfa) Listing Decision

Customer Letter 2024-21 (PDF)

CL_2024-20.pdf

INFORMATION ONLY
WinRho Label Change

Customer Letter 2024-20 (PDF) | Change of Packaging WinRho® 600 IU 120mcg (PDF)

CL_2024-19.pdf

INFORMATION ONLY
Manitoba Hospital Customers Only, Change of Testing Location for Disease Associated Markers

Customer Letter 2024-19 (PDF)

CL_2024-18.pdf

INFORMATION ONLY
Testing Changes, Change of Testing Location

Customer Letter 2024-18 (PDF)

CL_2024-17.pdf

INFORMATION ONLY
New Tamper Seals

Customer Letter 2024-17 (PDF)

CL_2024-16.pdf

INFORMATION ONLY
Octaplasma Label Changes

Customer Letter 2024-16 (PDF) | Enhanced Octaplasma® Labels for Canadian Customers (PDF)

CL_2024-15.pdf

INFORMATION ONLY
Takeda Product Updates

Customer Letter 2024-15 (PDF) | Takeda Letter (PDF)

CL_2024-14.pdf

INFORMATION ONLY
Release of Revised Circulars of Information for Pooled Platelets Psoralen Treated, Apheresis Platelets Psoralen Treated and Apheresis Platelets PAS Added

Customer Letter 2024-14 (PDF)

CL_2024-13.pdf

INFORMATION ONLY
Further updates to Ig Transitions FAQ regarding the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP)

Customer Letter 2024-13 (PDF) | 2024 Ig Transition FAQ (PDF)

CL_2024-12.pdf

INFORMATION ONLY
Hizentra 20% 10g Pre-Filled Syringe Update

Customer Letter 2024-12 (PDF) | Hizentra® 50mL Pre-filled Syringe (PDF)Hizentra® Tool (PDF)

CL_2024-11.pdf

INFORMATION ONLY
Glassia Update

Customer Letter 2024-11 (PDF) | Glassia Implementation FAQ (PDF)

CL_2024-10.pdf

ACTION REQUIRED
National Deployment of Pathogen-Reduced Platelets: Sixth Update 

Customer Letter 2024-10 (PDF)

CL_2024-09.pdf

INFORMATION ONLY
Introducing Hizentra 20% 10g Pre-Filled Syringe

Customer Letter 2024-09 (PDF)

CL_2024-08.pdf

INFORMATION ONLY
Temporary Changes to Gammagard S/D

Customer Letter 2024-08 (PDF) | GAMMAGARD® Customer Letter (PDF)

CL_2024-07.pdf

INFORMATION ONLY
Updated FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP)

Customer Letter 2024-07 (PDF) | 2024 Ig Transition FAQ (PDF)

CL_2024-06.pdf

INFORMATION ONLY
Updated NAC Recommendations for Use of Irradiated Blood Components in Canada

Customer Letter 2024-06 (PDF)

CL_2024-05.pdf

ACTION REQUIRED
New Visual Inspection Tool (VIT)

Customer Letter 2024-05 (PDF)

CL_2024-04.pdf

INFORMATION ONLY
Glassia Launch Update

Customer Letter 2024-04 (PDF) | Introducing GLASSIA® in Canada (PDF)

CL_2024-03.pdf

INFORMATION ONLY
Introducing Rebinyn 3000IU and Esperoct 3000IU

Customer Letter 2024-03 (PDF)

CL_2024-02.pdf

INFORMATION ONLY
Illegible Lots on CSL’s Alburex 25% 100mL

Customer Letter 2024-02 (PDF) | Variable Printed Information on Alburex-25 Cartons (PDF)

CL_2024-01.pdf

INFORMATION ONLY
Discontinuation of Directed Donations

Customer Letter 2024-01 (PDF)